Filter
1461
Text search:
dosage
Featured
197
424
Language
Document type
844
298
150
63
44
21
16
8
7
4
4
1
1
Countries / Regions
108
45
44
39
38
29
28
26
26
25
20
20
19
19
18
18
17
16
15
15
13
13
13
12
12
12
10
10
8
8
8
8
7
7
6
6
6
5
5
5
4
4
4
4
4
3
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
607
228
95
71
27
22
18
1
1
Toolboxes
127
113
99
91
74
65
44
39
36
33
22
15
13
13
10
9
8
6
5
5
5
2
Second edition
Q3: For behavioural and psychological symptoms in people with dementia, do following drugs, when compared to placebo/comparator, produce benefits/harm in the specified outcomes?
Guide for community-based management and care of people with dementia
Version 1.0
Mental Health and Substance Abuse
Division of NCD and Health through the Life-Course
World Health Organization Regional Office for the Western Pacific
Scoping Question: For adults and children living with HIV, which antiepileptic medications (such as phenobarbital, phenytoin, carbamazepine or valproic acid) produce benefits and/or harms when compared to a placebo or controls?
SCOPING QUESTION: In adults with established status epilepticus (i.e., seizures persisting after the first-line treatment with benzodiazepines [or benzodiazepines-resistant status epilepticus]), which anti-epileptic medications are associated with cessation of seizures and reduced adverse effects)?
...
Published: 5 January 2010 Received: 30 January 2009
BMC Neurology 2010, 10:1 doi:10.1186/1471-2377-10-1
This article is available from: http://www.biomedcentral.com/1471-2377/10/1
J Mov Disord > Volume 11(2); 2018 > Article
Review Article
J Mov Disord 2018; 11(2): 53-64.
Published online: May 30, 2018
DOI: https://doi.org/10.14802/jmd.17028
Print version ISSN 1809-9823On-line version ISSN 1981-2256
Rev. bras. geriatr. gerontol. vol.19 no.2 Rio de Janeiro Mar./Apr. 2016
http://dx.doi.org/10.1590/1809-98232016019.150040
A Manual for Medical Officer
Developed under the Government of India – WHO Collaborative Programme 2008-2009
Accessed: 11.03.2019
An update from the EU Early Warning System
Assessing and improving quality and human rights in mental health and social care facilites
Amphetamine-type stimulants, new psychoactive substances
-4-
World Drug Report 2017
Accessed: 14.03.2019
World Drug Report 2017
-1-
Accessed: 14.03.2019
This report, written in partnership with various Royal Medical Colleges and Public Health England, sets out the essential actions to improve the physical health of adults with severe mental illness (SMI) across the NHS. The report makes practical recommendations for changes that will help adults wit
...
Tobacco control legislation: an introductory guide
Position Statement
Diabetes Care2018;42(Suppl. 1):S1–S194.
Reduced healthy life expectancy due to the high burden of both mental ill health and noncommunicable diseases (NCDs) is a major public health concern in the European Region. The links between mental disorders and major NCDs are well established.
In clinical practice, however, mental disorders in pa
...
